Wells Fargo & Company Has Lowered Expectations for Agilent Technologies (NYSE:A) Stock Price

Agilent Technologies (NYSE:A) had its price target decreased by analysts at Wells Fargo & Company from $157.00 to $155.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical research company’s stock. Wells Fargo & Company‘s price target points to a potential upside of 7.66% from the company’s current price.

A has been the topic of several other research reports. Citigroup lifted their price target on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. StockNews.com cut Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, November 26th. Stifel Nicolaus restated a “buy” rating and set a $151.00 price objective on shares of Agilent Technologies in a research note on Monday, August 26th. UBS Group upped their target price on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Finally, Evercore ISI raised their price target on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $143.14.

Agilent Technologies Trading Up 2.4 %

A traded up $3.39 during midday trading on Monday, hitting $143.97. The company’s stock had a trading volume of 214,359 shares, compared to its average volume of 1,721,692. Agilent Technologies has a 52-week low of $124.16 and a 52-week high of $155.35. The firm has a 50-day moving average price of $137.23 and a two-hundred day moving average price of $136.64. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57. The firm has a market cap of $41.37 billion, a P/E ratio of 32.57, a PEG ratio of 4.46 and a beta of 1.07.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.05. The company had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The business’s quarterly revenue was up .8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.38 EPS. On average, research analysts anticipate that Agilent Technologies will post 5.56 earnings per share for the current year.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. The trade was a 19.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of A. Menard Financial Group LLC lifted its position in Agilent Technologies by 1.6% in the 2nd quarter. Menard Financial Group LLC now owns 4,845 shares of the medical research company’s stock worth $628,000 after buying an additional 77 shares in the last quarter. McAdam LLC raised its holdings in shares of Agilent Technologies by 3.1% during the third quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock worth $376,000 after acquiring an additional 77 shares in the last quarter. Brown Brothers Harriman & Co. raised its holdings in shares of Agilent Technologies by 13.5% during the third quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock worth $96,000 after acquiring an additional 77 shares in the last quarter. Global Retirement Partners LLC boosted its position in Agilent Technologies by 3.2% during the third quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock valued at $382,000 after purchasing an additional 79 shares during the last quarter. Finally, Rovin Capital UT ADV grew its stake in Agilent Technologies by 1.6% in the third quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock valued at $750,000 after purchasing an additional 81 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.